
XFOR Stock Forecast & Price Target
XFOR Analyst Ratings
Bulls say
X4 Pharmaceuticals Inc has demonstrated a proactive approach in its clinical development strategy by increasing the enrollment target for the pivotal 4WARD study to 176 participants, ensuring a comprehensive data package for regulatory review. The anticipated label expansion of mavorixafor into additional primary immunodeficiency disorders, coupled with robust biological validation for CXCR4 inhibition, positions the company for potentially significant market opportunities. Furthermore, a successful financing round has bolstered the company's cash position, projecting approximately $130 million by the end of the third quarter of 2025, which enhances its financial flexibility to support ongoing and future development initiatives.
Bears say
The analysis indicates several fundamental concerns regarding X4 Pharmaceuticals's financial outlook. Key issues include a significant decrease in the projected target price from $30 to $9, driven largely by delayed patient enrollment timelines for the 4WARD trial and reduced sales estimates for its WHIM syndrome treatment, leading to expectations of peak sales dropping from approximately $140 million to $75-80 million. Additionally, the company faces a challenging balance sheet situation exacerbated by anticipated dilution from PIPE and ATM financing, leading to further uncertainty regarding future funding requirements amid ongoing operational and strategic reviews by new management.
This aggregate rating is based on analysts' research of X4 Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
XFOR Analyst Forecast & Price Prediction
Start investing in XFOR
Order type
Buy in
Order amount
Est. shares
0 shares